Ipilimumab is a medication used in the management and treatment of metastatic melanoma. It is in the CTLA-4 monoclonal antibody class of drugs. This activity illustrates the indications, action, and contraindications for Ipilimumab as a valuable agent in managing metastatic melanoma and several other tumors. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the healthcare team in the management of patients with metastatic melanoma and related conditions.
Copyright © 2024, StatPearls Publishing LLC.